Results 61 to 70 of about 60,346 (233)

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

European Journal of Haematology, EarlyView.
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B

Brazilian Journal of Infectious Diseases
BACKGROUND AND AIM: Chronic hepatitis B is a highly prevalent disease worldwide, leading to serious consequences if not properly treated. Six treatment options for chronic hepatitis B are currently provided by the Brazilian public health system ...
Astrid Wiens, Rafael Venson, Cassyano Januário Correr, Roberto Pontarolo   +3 more
doaj   +1 more source

Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir [PDF]

, 2014
There are few clinical data on the combination abacavir/lamivudine plus raltegravir. We compared the outcomes of patients from the SPIRAL trial receiving either abacavir/lamivudine or tenofovir/emtricitabine at baseline who had taken at least one dose of
D'Albuquerque, Polyana M., Gatell, José M., Martínez Chamorro, Esteban José, Pich, Judit, Pérez Catalán, Ignacio   +4 more
core   +2 more sources

Informal PrEP use in Greece: The long, hard road to formal programmatic implementation

HIV Medicine, EarlyView.
Abstract Objectives Pre‐exposure prophylaxis (PrEP) with antiretroviral drugs (ARVs) is a highly effective HIV prevention strategy. Although the European Medicines Agency approved oral PrEP in 2016 and the World Health Organization (WHO) has since recommended simplified and person‐centred delivery models, implementation remains inconsistent across ...
Konstantinos Protopapas, Charalampos D. Moschopoulos, Nikolaos Kalesis, Ioannis Mameletzis   +3 more
wiley   +1 more source

Top-Down Synthesis of a Lamivudine-Zidovudine Nano Co-Crystal

Crystals, 2020
Lamivudine (3TC) and zidovudine (AZT) are antiretroviral agents used to manage HIV/AIDS infection. A wet media milling top-down approach was used to develop and produce nano co-crystals of 3TC and AZT.
Bwalya A. Witika, Vincent J. Smith, Roderick B. Walker   +2 more
doaj   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

Clinical trial of lamivudine in children with chronic hepatitis B. [PDF]

, 2002
N Engl J Med. 2002 May 30;346(22):1706-13. Clinical trial of lamivudine in children with chronic hepatitis B. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM; International Pediatric ...
Areias, J.A., Badia, I.B., Bell, M.S., Gardner, S.D., Greensmith, M.J., International Pediatric Lamivudine Investigator Group., Jonas, M.M., Little, N.R., Mizerski, J., Schwarz, K.B., Sokal, E.M.   +10 more
core   +1 more source

Prevalence of Sleep Apnea and Sleepiness in Adults With and Without HIV in Mwanza, Tanzania: Baseline Results From an Ongoing Cohort Study

Journal of Sleep Research, EarlyView.
ABSTRACT We conducted a cross‐sectional analysis of the baseline survey of participants aged > 30 years enrolled in the Mwanza HIV&CVD Cohort in Tanzania. Our primary objective was to examine the association between HIV status and sleep apnea (SA).
Godfrey A. Kisigo, Benson Issarow, Salama Fadhil, Grace Ruselu, Ponsiano Fabian, Ayubu Garbindi, Robert N. Peck, Kathy Baisley, Saidi Kapiga, Ana C. Krieger   +9 more
wiley   +1 more source

Method development and validation for multi-component analysis of lamivudine & tenofovir disoproxil fumarate in bulk drug by UV-visible spectrophotometer & RP-HPLC

Journal of Applied Pharmaceutical Research, 2020
A novel, simple, precise and accurate method developed for the estimation of Lamivudine and tenofovir disoproxil fumarate (TDF) in bulk drug form has been established. Lamivudine and tenofovir are well known drugs and used in treatment of HIV- Ⅰ.
Shweta Sharma, Amar Deep Ankalgi, Pooja Kaushal, M. S. Ashawat   +3 more
doaj   +1 more source

Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia [PDF]

, 2011
Objectives  To report immunovirological outcomes and resistance patterns in adults treated with triple combination antiretroviral therapy (cART) for 4 years in an HIV programme of Phnom Penh, Cambodia.
Balkan, Suna, Chanchhaya, Ngeth, Ferradini, Laurent, Narom, Prak, Nerrienet, Eric, Pujades-Rodríguez, Mar, Schramm, Birgit, Som, Leakena   +7 more
core   +2 more sources